{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:40Z","timestamp":1792079680042,"version":"4.4.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/nrrheum.2018.31","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T04:59:28Z","timestamp":1521608368000},"page":"214-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":311,"title":["Type I interferon in rheumatic diseases"],"prefix":"10.1038","volume":"14","author":[{"given":"Theresa L. Wampler","family":"Muskardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Niewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"BFnrrheum201831_CR1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/521373","volume":"81","author":"G Rice","year":"2007","unstructured":"Rice, G. et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 81, 713\u2013725 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201831_CR2","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610\u20132615 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201831_CR3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","volume":"197","author":"L Bennett","year":"2003","unstructured":"Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711\u2013723 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum201831_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/ar1015","volume":"5","author":"MK Crow","year":"2003","unstructured":"Crow, M. K. & Wohlgemuth, J. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 5, 279\u2013287 (2003).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/gene.2014.57","volume":"16","author":"SN Kariuki","year":"2015","unstructured":"Kariuki, S. N. et al. Genetic analysis of the pathogenic molecular sub-phenotype interferon-\u03b1 identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun. 16, 15\u201323 (2015).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"BFnrrheum201831_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8\u201332 (2004).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum201831_CR8","first-page":"23","volume":"316","author":"S Pestka","year":"2007","unstructured":"Pestka, S. Purification and cloning of interferon \u03b1. Curr. Top. Microbiol. Immunol. 316, 23\u201337 (2007).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFnrrheum201831_CR9","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2005-07-2709","volume":"107","author":"T Ito","year":"2006","unstructured":"Ito, T., Kanzler, H., Duramad, O., Cao, W. & Liu, Y. J. Specialization, kinetics, and repertoire of type I interferon responses by human plasmacytoid predendritic cells. Blood 107, 2423\u20132431 (2006).","journal-title":"Blood"},{"key":"BFnrrheum201831_CR10","doi-asserted-by":"crossref","first-page":"18651","DOI":"10.1074\/jbc.M501289200","volume":"280","author":"A Prakash","year":"2005","unstructured":"Prakash, A., Smith, E., Lee, C. K. & Levy, D. E. Tissue-specific positive feedback requirements for production of type I interferon following virus infection. J. Biol. Chem. 280, 18651\u201318657 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201831_CR11","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.4049\/jimmunol.178.10.6208","volume":"178","author":"M Severa","year":"2007","unstructured":"Severa, M. et al. Sensitization to TLR7 agonist in IFN-\u03b2-preactivated dendritic cells. J. Immunol. 178, 6208\u20136216 (2007).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR12","doi-asserted-by":"crossref","first-page":"14242","DOI":"10.1016\/S0021-9258(17)38709-4","volume":"260","author":"U Nir","year":"1985","unstructured":"Nir, U., Maroteaux, L., Cohen, B. & Mory, I. Priming affects the transcription rate of human interferon-\u03b21 gene. J. Biol. Chem. 260, 14242\u201314247 (1985).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201831_CR13","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.4049\/jimmunol.1103491","volume":"189","author":"G Weiss","year":"2012","unstructured":"Weiss, G. et al. MyD88 drives the IFN-\u03b2 response to Lactobacillus acidophilus in dendritic cells through a mechanism involving IRF1, IRF3, and IRF7. J. Immunol. 189, 2860\u20132868 (2012).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","volume":"7","author":"T Kawai","year":"2006","unstructured":"Kawai, T. & Akira, S. Innate immune recognition of viral infection. Nat. Immunol. 7, 131\u2013137 (2006).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum201831_CR15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fgene.2014.00418","volume":"5","author":"L Oliveira","year":"2014","unstructured":"Oliveira, L., Sinicato, N. A., Postal, M., Appenzeller, S. & Niewold, T. B. Dysregulation of antiviral helicase pathways in systemic lupus erythematosus. Front. Genet. 5, 418 (2014).","journal-title":"Front. Genet."},{"key":"BFnrrheum201831_CR16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ng1845","volume":"38","author":"YJ Crow","year":"2006","unstructured":"Crow, Y. J. et al. Mutations in the gene encoding the 3\u2032-5\u2032 DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38, 917\u2013920 (2006).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201831_CR17","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","volume":"68","author":"CP Mavragani","year":"2016","unstructured":"Mavragani, C. P. et al. Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheumatol. 68, 2686\u20132696 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201831_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.immuni.2017.02.011","volume":"46","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. Immunity 46, 393\u2013404 (2017).","journal-title":"Immunity"},{"key":"BFnrrheum201831_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","volume":"26","author":"T Tamura","year":"2008","unstructured":"Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535\u2013584 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum201831_CR20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783\u2013801 (2006).","journal-title":"Cell"},{"key":"BFnrrheum201831_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fimmu.2013.00319","volume":"4","author":"M Shrivastav","year":"2013","unstructured":"Shrivastav, M. & Niewold, T. B. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front. Immunol. 4, 319 (2013).","journal-title":"Front. Immunol."},{"key":"BFnrrheum201831_CR22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","volume":"32","author":"AL Blasius","year":"2010","unstructured":"Blasius, A. L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305\u2013315 (2010).","journal-title":"Immunity"},{"key":"BFnrrheum201831_CR23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trsl.2014.10.002","volume":"165","author":"MA Jensen","year":"2015","unstructured":"Jensen, M. A. & Niewold, T. B. Interferon regulatory factors: critical mediators of human lupus. Transl Res. 165, 283\u2013295 (2015).","journal-title":"Transl Res."},{"key":"BFnrrheum201831_CR24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ni1576","volume":"9","author":"A Yarilina","year":"2008","unstructured":"Yarilina, A., Park-Min, K. H., Antoniv, T., Hu, X. & Ivashkiv, L. B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9, 378\u2013387 (2008).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum201831_CR25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.immuni.2013.01.012","volume":"38","author":"D Venkatesh","year":"2013","unstructured":"Venkatesh, D. et al. Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-\u03b2 autocrine signaling to promote monocyte recruitment. Immunity 38, 1025\u20131037 (2013).","journal-title":"Immunity"},{"key":"BFnrrheum201831_CR26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/416744a","volume":"416","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi, H. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-\u03b2. Nature 416, 744\u2013749 (2002).","journal-title":"Nature"},{"key":"BFnrrheum201831_CR27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jbspin.2015.07.010","volume":"83","author":"Q Xiong","year":"2016","unstructured":"Xiong, Q., Zhang, L., Ge, W. & Tang, P. The roles of interferons in osteoclasts and osteoclastogenesis. Joint Bone Spine 83, 276\u2013281 (2016).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum201831_CR28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","volume":"14","author":"NA de Weerd","year":"2013","unstructured":"de Weerd, N. A. et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14, 901\u2013907 (2013).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum201831_CR29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum201831_CR30","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs, S. et al. Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res. 17, 2619\u20132627 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrrheum201831_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2015.04.002","volume":"60","author":"S Sharma","year":"2015","unstructured":"Sharma, S. et al. Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. J. Autoimmun. 60, 51\u201358 (2015).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum201831_CR32","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1093\/emboj\/18.20.5601","volume":"18","author":"KC Goh","year":"1999","unstructured":"Goh, K. C., Haque, S. J. & Williams, B. R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18, 5601\u20135608 (1999).","journal-title":"EMBO J."},{"key":"BFnrrheum201831_CR33","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1073\/pnas.0710907105","volume":"105","author":"S Kaur","year":"2008","unstructured":"Kaur, S. et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl Acad. Sci. USA 105, 4808\u20134813 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201831_CR34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/cr.2013.47","volume":"23","author":"K Fink","year":"2013","unstructured":"Fink, K. et al. IFN\u03b2\/TNF\u03b1 synergism induces a non-canonical STAT2\/IRF9-dependent pathway triggering a novel DUOX2 NADPH oxidase-mediated airway antiviral response. Cell Res. 23, 673\u2013690 (2013).","journal-title":"Cell Res."},{"key":"BFnrrheum201831_CR35","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs, B. W. et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029\u20132036 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR36","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/art.24449","volume":"60","author":"T Karonitsch","year":"2009","unstructured":"Karonitsch, T. et al. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum. 60, 1463\u20131471 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR37","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.cell.2016.05.057","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 1548\u20131550 (2016).","journal-title":"Cell"},{"key":"BFnrrheum201831_CR38","doi-asserted-by":"crossref","first-page":"e67003","DOI":"10.1371\/journal.pone.0067003","volume":"8","author":"AM Becker","year":"2013","unstructured":"Becker, A. M. et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS ONE 8, e67003 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201831_CR39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.30187","volume":"63","author":"CE Weckerle","year":"2011","unstructured":"Weckerle, C. E. et al. Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 63, 1044\u20131053 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/107999099313901","volume":"19","author":"WJ Jabs","year":"1999","unstructured":"Jabs, W. J., Hennig, C., Zawatzky, R. & Kirchner, H. Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-\u03b1 and IFN-\u03b2. J. Interferon Cytokine Res. 19, 463\u2013469 (1999).","journal-title":"J. Interferon Cytokine Res."},{"key":"BFnrrheum201831_CR41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","volume":"21","author":"DR Wilson","year":"2016","unstructured":"Wilson, D. R. et al. The Simoa HD-I analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J. Lab. Autom. 21, 533\u2013547 (2016).","journal-title":"J. Lab. Autom."},{"key":"BFnrrheum201831_CR42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595\u2013599 (2010).","journal-title":"Nat. Biotechnol."},{"key":"BFnrrheum201831_CR43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cell.2016.06.024","volume":"166","author":"S Meyer","year":"2016","unstructured":"Meyer, S. et al. AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166, 582\u2013595 (2016).","journal-title":"Cell"},{"key":"BFnrrheum201831_CR44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","volume":"227","author":"LE Ronnblom","year":"1990","unstructured":"Ronnblom, L. E., Alm, G. V. & Oberg, K. E. Possible induction of systemic lupus erythematosus by interferon-\u03b1 treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 227, 207\u2013210 (1990).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201831_CR45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10067-004-1024-2","volume":"24","author":"TB Niewold","year":"2005","unstructured":"Niewold, T. B. & Swedler, W. I. Systemic lupus erythematosus arising during interferon-\u03b1 therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin. Rheumatol. 24, 178\u2013181 (2005).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201831_CR46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","volume":"8","author":"TB Niewold","year":"2007","unstructured":"Niewold, T. B., Hua, J., Lehman, T. J., Harley, J. B. & Crow, M. K. High serum IFN-\u03b1 activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 8, 492\u2013502 (2007).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR47","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar3101","volume":"12","author":"SN Kariuki","year":"2010","unstructured":"Kariuki, S. N. et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res. Ther. 12, R151 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR48","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","volume":"75","author":"ME Munroe","year":"2016","unstructured":"Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014\u20132021 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"BFnrrheum201831_CR49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2217\/ijr.13.58","volume":"8","author":"Yogita Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik, Y. & Niewold, T. B. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int. J. Clin. Rheumtol. https:\/\/doi.org\/10.2217\/ijr.13.58 (2013).","journal-title":"International Journal of Clinical Rheumatology"},{"key":"BFnrrheum201831_CR50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.182.1.34","volume":"182","author":"SN Kariuki","year":"2009","unstructured":"Kariuki, S. N. et al. Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-\u03b1 in lupus patients in vivo. J. Immunol. 182, 34\u201338 (2009).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR51","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4049\/jimmunol.1100857","volume":"187","author":"T Robinson","year":"2011","unstructured":"Robinson, T. et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-\u03b1 and serologic autoimmunity in lupus patients. J. Immunol. 187, 1298\u20131303 (2011).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR52","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.1074\/jbc.M101216200","volume":"276","author":"BJ Barnes","year":"2001","unstructured":"Barnes, B. J., Moore, P. A. & Pitha, P. M. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon \u03b1 genes. J. Biol. Chem. 276, 23382\u201323390 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum201831_CR53","doi-asserted-by":"crossref","first-page":"e103478","DOI":"10.1371\/journal.pone.0103478","volume":"9","author":"K Yasuda","year":"2014","unstructured":"Yasuda, K. et al. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL\/lpr mouse model of lupus in the absence of a mutation in DOCK2. PLoS ONE 9, e103478 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201831_CR54","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1073\/pnas.0701266104","volume":"104","author":"RR Graham","year":"2007","unstructured":"Graham, R. R. et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl Acad. Sci. USA 104, 6758\u20136763 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201831_CR55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.81","volume":"40","author":"JB Harley","year":"2008","unstructured":"Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204\u2013210 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201831_CR56","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.2792","volume":"45","author":"CJ Lessard","year":"2013","unstructured":"Lessard, C. J. et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj\u00f6gren's syndrome. Nat. Genet. 45, 1284\u20131292 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201831_CR57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","volume":"42","author":"TR Radstake","year":"2010","unstructured":"Radstake, T. R. et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 42, 426\u2013429 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201831_CR58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.23426","volume":"58","author":"R Dieguez-Gonzalez","year":"2008","unstructured":"Dieguez-Gonzalez, R. et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum. 58, 1264\u20131274 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR59","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/ker364","volume":"51","author":"GB Nordang","year":"2012","unstructured":"Nordang, G. B. et al. Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts. Rheumatology (Oxford) 51, 619\u2013626 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201831_CR60","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/art.23613","volume":"58","author":"TB Niewold","year":"2008","unstructured":"Niewold, T. B. et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58, 2481\u20132487 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/annrheumdis-2011-200463","volume":"71","author":"TB Niewold","year":"2012","unstructured":"Niewold, T. B. et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann. Rheum. Dis. 71, 463\u2013468 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR62","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/art.34571","volume":"64","author":"TS Cherian","year":"2012","unstructured":"Cherian, T. S. et al. Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 64, 3383\u20133387 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR63","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.30193","volume":"63","author":"Q Fu","year":"2011","unstructured":"Fu, Q. et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 63, 749\u2013754 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR64","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajhg.2012.02.023","volume":"90","author":"CJ Lessard","year":"2012","unstructured":"Lessard, C. J. et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 90, 648\u2013660 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201831_CR65","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.27182","volume":"62","author":"R Salloum","year":"2010","unstructured":"Salloum, R. et al. Genetic variation at the IRF7\/PHRF1 locus is associated with autoantibody profile and serum interferon-\u03b1 activity in lupus patients. Arthritis Rheum. 62, 553\u2013561 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR66","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/gene.2013.42","volume":"14","author":"BS Chrabot","year":"2013","unstructured":"Chrabot, B. S. et al. Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 14, 471\u2013478 (2013).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/emmm.201000120","volume":"3","author":"J Pothlichet","year":"2011","unstructured":"Pothlichet, J. et al. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med. 3, 142\u2013152 (2011).","journal-title":"EMBO Mol. Med."},{"key":"BFnrrheum201831_CR68","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/art.23728","volume":"58","author":"SN Kariuki","year":"2008","unstructured":"Kariuki, S. N., Crow, M. K. & Niewold, T. B. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-\u03b1 activity and low tumor necrosis factor \u03b1 levels in patients with lupus. Arthritis Rheum. 58, 2818\u20132823 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR69","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2013.06.013","volume":"39","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type I interferon-dependent immunity. Immunity 39, 111\u2013122 (2013).","journal-title":"Immunity"},{"key":"BFnrrheum201831_CR70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/gene.2010.29","volume":"11","author":"N Gestermann","year":"2010","unstructured":"Gestermann, N. et al. STAT4 is a confirmed genetic risk factor for Sj\u00f6gren's syndrome and could be involved in type I interferon pathway signaling. Genes Immun. 11, 432\u2013438 (2010).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR71","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/art.24688","volume":"60","author":"P Dieude","year":"2009","unstructured":"Dieude, P. et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 60, 2472\u20132479 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR72","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","volume":"357","author":"EF Remmers","year":"2007","unstructured":"Remmers, E. F. et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357, 977\u2013986 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201831_CR73","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.humimm.2009.05.008","volume":"70","author":"MI Zervou","year":"2009","unstructured":"Zervou, M. I., Goulielmos, G. N., Castro-Giner, F., Tosca, A. D. & Krueger-Krasagakis, S. STAT4 gene polymorphism is associated with psoriasis in the genetically homogeneous population of Crete, Greece. Hum. Immunol. 70, 738\u2013741 (2009).","journal-title":"Hum. Immunol."},{"key":"BFnrrheum201831_CR74","doi-asserted-by":"crossref","first-page":"8873","DOI":"10.1007\/s11033-012-1754-1","volume":"39","author":"YL Liang","year":"2012","unstructured":"Liang, Y. L. et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol. Biol. Rep. 39, 8873\u20138882 (2012).","journal-title":"Mol. Biol. Rep."},{"key":"BFnrrheum201831_CR75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjd.13340","volume":"172","author":"HL Hebert","year":"2015","unstructured":"Hebert, H. L. et al. Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. Br. J. Dermatol. 172, 933\u2013939 (2015).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum201831_CR76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/kel170","volume":"46","author":"YH Lee","year":"2007","unstructured":"Lee, Y. H. et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases \u2014 a meta-analysis. Rheumatology (Oxford) 46, 49\u201356 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201831_CR77","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/468189","volume":"77","author":"VE Carlton","year":"2005","unstructured":"Carlton, V. E. et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 77, 567\u2013581 (2005).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201831_CR78","doi-asserted-by":"crossref","first-page":"e000183","DOI":"10.1136\/lupus-2016-000183","volume":"3","author":"A Mok","year":"2016","unstructured":"Mok, A. et al. Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type I interferon responses. Lupus Sci. Med. 3, e000183 (2016).","journal-title":"Lupus Sci. Med."},{"key":"BFnrrheum201831_CR79","first-page":"706825","volume":"2010","author":"ITW Harley","year":"2010","unstructured":"Harley, I. T. W. et al. The role of genetic variation near interferon-\u03ba in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 706825 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"BFnrrheum201831_CR80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2016.09.008","volume":"137","author":"JN Stannard","year":"2017","unstructured":"Stannard, J. N. et al. Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop. J. Invest. Dermatol. 137, 115\u2013122 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum201831_CR81","first-page":"309","volume":"4","author":"K Ko","year":"2013","unstructured":"Ko, K., Koldobskaya, Y., Rosenzweig, E. & Niewold, T. B. Activation of the interferon pathway is dependent upon autoantibodies in African-American SLE patients, but not in European-American SLE patients. Frontiers Immunol. 4, 309 (2013).","journal-title":"Frontiers Immunol."},{"key":"BFnrrheum201831_CR82","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.4049\/jimmunol.1003349","volume":"186","author":"N Hagberg","year":"2011","unstructured":"Hagberg, N. et al. IFN-\u03b1 production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes is promoted by NK cells via MIP-1\u03b2 and LFA-1. J. Immunol. 186, 5085\u20135094 (2011).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR83","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.40304","volume":"69","author":"Y Ghodke-Puranik","year":"2017","unstructured":"Ghodke-Puranik, Y. et al. Lupus-associated functional polymorphism in PNP causes cell cycle abnormalities and interferon pathway activation in human immune cells. Arthritis Rheumatol. 69, 2328\u20132337 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201831_CR84","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","volume":"68","author":"C Landolt-Marticorena","year":"2009","unstructured":"Landolt-Marticorena, C. et al. Lack of association between the interferon-\u03b1 signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 68, 1440\u20131446 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR85","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203309105529","volume":"18","author":"M Petri","year":"2009","unstructured":"Petri, M. et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18, 980\u2013989 (2009).","journal-title":"Lupus"},{"key":"BFnrrheum201831_CR86","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","volume":"60","author":"JW Bauer","year":"2009","unstructured":"Bauer, J. W. et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60, 3098\u20133107 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR87","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","volume":"52","author":"TO Hjelmervik","year":"2005","unstructured":"Hjelmervik, T. O., Petersen, K., Jonassen, I., Jonsson, R. & Bolstad, A. I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren's syndrome patients from healthy control subjects. Arthritis Rheum. 52, 1534\u20131544 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR88","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","volume":"10","author":"ES Emamian","year":"2009","unstructured":"Emamian, E. S. et al. Peripheral blood gene expression profiling in Sj\u00f6gren's syndrome. Genes Immun. 10, 285\u2013296 (2009).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR89","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","volume":"103","author":"JE Gottenberg","year":"2006","unstructured":"Gottenberg, J. E. et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome. Proc. Natl Acad. Sci. USA 103, 2770\u20132775 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum201831_CR90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/art.23191","volume":"58","author":"TB Niewold","year":"2008","unstructured":"Niewold, T. B., Rivera, T. L., Buyon, J. P. & Crow, M. K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA\/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 58, 541\u2013546 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR91","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic, Z. et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 72, 728\u2013735 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR92","doi-asserted-by":"crossref","first-page":"e1006820","DOI":"10.1371\/journal.pgen.1006820","volume":"13","author":"H Li","year":"2017","unstructured":"Li, H. et al. Identification of a Sj\u00f6gren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genet. 13, e1006820 (2017).","journal-title":"PLoS Genet."},{"key":"BFnrrheum201831_CR93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clim.2016.10.015","volume":"173","author":"NI Vlachogiannis","year":"2016","unstructured":"Vlachogiannis, N. I. et al. Increased frequency of the PTPN22W* variant in primary Sj\u00f6gren's syndrome: association with low type I IFN scores. Clin. Immunol. 173, 157\u2013160 (2016).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum201831_CR94","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2016-209589","volume":"76","author":"NI Maria","year":"2017","unstructured":"Maria, N. I. et al. Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sj\u00f6gren's syndrome. Ann. Rheum. Dis. 76, 721\u2013730 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","volume":"63","author":"A Nezos","year":"2015","unstructured":"Nezos, A. et al. Type I and II interferon signatures in Sj\u00f6gren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sj\u00f6gren's related lymphomagenesis. J. Autoimmun. 63, 47\u201358 (2015).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum201831_CR96","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold, T. B., Kariuki, S. N., Morgan, G. A., Shrestha, S. & Pachman, L. M. Elevated serum interferon-\u03b1 activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 60, 1815\u20131824 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","volume":"120","author":"KA O'Connor","year":"2006","unstructured":"O'Connor, K. A., Abbott, K. A., Sabin, B., Kuroda, M. & Pachman, L. M. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin. Immunol. 120, 319\u2013325 (2006).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum201831_CR98","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/art.27529","volume":"62","author":"S Shrestha","year":"2010","unstructured":"Shrestha, S. et al. Lesional and non lesional skin from untreated juvenile dermatomyositis (JDM) displays increased mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 62, 2813\u20132822 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR99","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed, A. M. et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 64, 4078\u20134086 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg, S. A. et al. Relationship between disease activity and type I interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 13, 207\u2013213 (2012).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR101","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jpeds.2010.04.034","volume":"157","author":"TB Niewold","year":"2010","unstructured":"Niewold, T. B., Kariuki, S. N., Morgan, G. A., Shrestha, S. & Pachman, L. M. Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon \u03b1 phenotype in juvenile dermatomyositis. J. Pediatr. 157, 653\u2013657 (2010).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201831_CR102","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1542\/peds.2010-3022","volume":"127","author":"TB Niewold","year":"2011","unstructured":"Niewold, T. B., Wu, S. C., Smith, M., Morgan, G. A. & Pachman, L. M. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 127, e1239\u2013e1246 (2011).","journal-title":"Pediatrics"},{"key":"BFnrrheum201831_CR103","doi-asserted-by":"crossref","unstructured":"Balboni, I. et al. Detection of anti-Ro, La, Smith and RNP autoantibodies by autoantigen microarray analysis and interferon-\u03b1 induction in juvenile dermatomyositis. Arthritis Rheum. 2424\u20132429 (2013).","DOI":"10.1002\/art.38038"},{"key":"BFnrrheum201831_CR104","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi, M. et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67, 1670\u20131677 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR105","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","volume":"56","author":"CP Mavragani","year":"2007","unstructured":"Mavragani, C. P. et al. Augmented interferon-\u03b1 pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept. Arthritis Rheum. 56, 3995\u20134004 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR106","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/ard.2010.139949","volume":"70","author":"AP Liao","year":"2011","unstructured":"Liao, A. P. et al. Interferon \u03b2 is associated with type I interferon-inducible gene expression in dermatomyositis. Ann. Rheum. Dis. 70, 831\u2013836 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR107","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/art.33350","volume":"64","author":"A Tournadre","year":"2012","unstructured":"Tournadre, A., Lenief, V., Eljaafari, A. & Miossec, P. Immature muscle precursors are a source of interferon-\u03b2 in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum. 64, 533\u2013541 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2015.06.009","volume":"285","author":"L Li","year":"2015","unstructured":"Li, L. et al. Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis. J. Neuroimmunol. 285, 161\u2013168 (2015).","journal-title":"J. Neuroimmunol."},{"key":"BFnrrheum201831_CR109","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","volume":"62","author":"S Assassi","year":"2010","unstructured":"Assassi, S. et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 62, 589\u2013598 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR110","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic, Z. et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis. 75, 1567\u20131573 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR111","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","volume":"56","author":"MR York","year":"2007","unstructured":"York, M. R. et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum. 56, 1010\u20131020 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","volume":"66","author":"RB Christmann","year":"2014","unstructured":"Christmann, R. B. et al. Association of Interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 66, 714\u2013725 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201831_CR113","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/03009742.2012.736532","volume":"42","author":"DM Wuttge","year":"2013","unstructured":"Wuttge, D. M. et al. Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sj\u00f6gren's syndrome antigens and nuclear ribonucleoprotein antigens. Scand. J. Rheumatol. 42, 235\u2013240 (2013).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201831_CR114","doi-asserted-by":"crossref","first-page":"e1004005","DOI":"10.1371\/journal.pcbi.1004005","volume":"11","author":"JM Mahoney","year":"2015","unstructured":"Mahoney, J. M. et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput. Biol. 11, e1004005 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"BFnrrheum201831_CR115","doi-asserted-by":"crossref","first-page":"e1002178","DOI":"10.1371\/journal.pgen.1002178","volume":"7","author":"O Gorlova","year":"2011","unstructured":"Gorlova, O. et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 7, e1002178 (2011).","journal-title":"PLoS Genet."},{"key":"BFnrrheum201831_CR116","doi-asserted-by":"crossref","first-page":"471703","DOI":"10.1155\/2013\/471703","volume":"2013","author":"N Barizzone","year":"2013","unstructured":"Barizzone, N. et al. Rare variants in the TREX1 gene and susceptibility to autoimmune diseases. Biomed. Res. Int. 2013, 471703 (2013).","journal-title":"Biomed. Res. Int."},{"key":"BFnrrheum201831_CR117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L van Bon","year":"2014","unstructured":"van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433\u2013443 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201831_CR118","doi-asserted-by":"crossref","first-page":"e2657","DOI":"10.1371\/journal.pone.0002657","volume":"3","author":"S Aidoudi","year":"2008","unstructured":"Aidoudi, S., Bujakowska, K., Kieffer, N. & Bikfalvi, A. The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis. PLoS ONE 3, e2657 (2008).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201831_CR119","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaci.2005.09.035","volume":"116","author":"P Romagnani","year":"2005","unstructured":"Romagnani, P. et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on T(H)1 or T-H cytokine production. J. Allergy Clin. Immunol. 116, 1372\u20131379 (2005).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrrheum201831_CR120","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.4049\/jimmunol.174.5.2680","volume":"174","author":"CY Liu","year":"2005","unstructured":"Liu, C. Y. et al. Platelet factor 4 differentially modulates CD4(+)CD25(+) (regulatory) versus CD4(+)CD25(-) (nonregulatory) T cells. J. Immunol. 174, 2680\u20132686 (2005).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR121","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/31.10.683","volume":"31","author":"W Stevens","year":"1992","unstructured":"Stevens, W., Vancheeswaran, R. & Black, C. M. Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. Br. J. Rheumatol 31, 683\u2013689 (1992).","journal-title":"Br. J. Rheumatol"},{"key":"BFnrrheum201831_CR122","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","volume":"42","author":"CM Black","year":"1999","unstructured":"Black, C. M. et al. Interferon-\u03b1 does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 42, 299\u2013305 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR123","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","volume":"72","author":"J Lubbers","year":"2013","unstructured":"Lubbers, J. et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann. Rheum. Dis. 72, 776\u2013780 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR124","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","volume":"54","author":"J Hua","year":"2006","unstructured":"Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906\u20131916 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/art.37804","volume":"65","author":"TU Han","year":"2013","unstructured":"Han, T. U. et al. Association of an activity-enhancing variant of IRAK1 and an MECP2-IRAK1 haplotype with increased susceptibility to rheumatoid arthritis. Arthritis Rheum. 65, 590\u2013598 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.20771","volume":"52","author":"G Orozco","year":"2005","unstructured":"Orozco, G. et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 52, 219\u2013224 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR127","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.4049\/jimmunol.173.4.2815","volume":"173","author":"R Lande","year":"2004","unstructured":"Lande, R. et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol. 173, 2815\u20132824 (2004).","journal-title":"J. Immunol."},{"key":"BFnrrheum201831_CR128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/ar1467","volume":"7","author":"LL Cavanagh","year":"2005","unstructured":"Cavanagh, L. L. et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res. Ther. 7, R230\u2013240 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR129","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1136\/ard.2005.040477","volume":"64","author":"J van Holten","year":"2005","unstructured":"van Holten, J., Smeets, T. J., Blankert, P. & Tak, P. P. Expression of interferon \u03b2 in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann. Rheum. Dis. 64, 1780\u20131782 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR130","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/ard.2007.086421","volume":"68","author":"MF Roelofs","year":"2009","unstructured":"Roelofs, M. F. et al. Type I interferons might form the link between Toll-like receptor (TLR) 3\/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann. Rheum. Dis. 68, 1486\u20131493 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR131","first-page":"345","volume":"8","author":"J Coclet-Ninin","year":"1997","unstructured":"Coclet-Ninin, J., Dayer, J. M. & Burger, D. Interferon-\u03b2 not only inhibits interleukin-1\u03b2 and tumor necrosis factor-\u03b1 but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw 8, 345\u2013349 (1997).","journal-title":"Eur. Cytokine Netw"},{"key":"BFnrrheum201831_CR132","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2002.005546","volume":"63","author":"G Palmer","year":"2004","unstructured":"Palmer, G. et al. Interferon \u03b2 stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann. Rheum. Dis. 63, 43\u201349 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR133","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A","volume":"42","author":"KA Triantaphyllopoulos","year":"1999","unstructured":"Triantaphyllopoulos, K. A., Williams, R. O., Tailor, H. & Chernajovsky, Y. Amelioration of collagen-induced arthritis and suppression of interferon-\u03b3, interleukin-12, and tumor necrosis factor alpha production by interferon-\u03b2 gene therapy. Arthritis Rheum. 42, 90\u201399 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR134","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1186\/ar1165","volume":"6","author":"J van Holten","year":"2004","unstructured":"van Holten, J. et al. Treatment with recombinant interferon-\u03b2 reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 6, R239\u2013R249 (2004).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2003.020347","volume":"64","author":"J van Holten","year":"2005","unstructured":"van Holten, J. et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon \u03b2-1a in the treatment of patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 64\u201369 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR136","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman, H. G. et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 14, R95 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.27226","volume":"62","author":"CP Mavragani","year":"2010","unstructured":"Mavragani, C. P., La, D. T., Stohl, W. & Crow, M. K. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-\u03b2\/\u03b1 ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 62, 392\u2013401 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR138","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2015-208001","volume":"75","author":"T Wampler Muskardin","year":"2016","unstructured":"Wampler Muskardin, T. et al. Increased pretreatment serum IFN-\u03b2\/\u03b1 ratio predicts non-response to tumour necrosis factor \u03b1 inhibition in rheumatoid arthritis. Ann. Rheum. Dis. 75, 1757\u20131762 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-016-0946-9","volume":"18","author":"TD de Jong","year":"2016","unstructured":"de Jong, T. D. et al. Physiological evidence for diversification of IFN\u03b1- and IFN\u03b2-mediated response programs in different autoimmune diseases. Arthritis Res. Ther. 18, 49 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR140","first-page":"345","volume":"8","author":"J Coclet-Ninin","year":"1997","unstructured":"Coclet-Ninin, J., Dayer, J. M. & Burger, D. Interferon-\u03b2 not only inhibits interleukin-1 \u03b2 and tumor necrosis factor-\u03b1 but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw. 8, 345\u2013349 (1997).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnrrheum201831_CR141","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","volume":"94","author":"H Kim","year":"2016","unstructured":"Kim, H., Sanchez, G. A. & Goldbach-Mansky, R. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J. Mol. Med. 94, 1111\u20131127 (2016).","journal-title":"J. Mol. Med."},{"key":"BFnrrheum201831_CR142","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.immuni.2013.05.004","volume":"38","author":"SR Paludan","year":"2013","unstructured":"Paludan, S. R. & Bowie, A. G. Immune sensing of DNA. Immunity 38, 870\u2013880 (2013).","journal-title":"Immunity"},{"key":"BFnrrheum201831_CR143","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/gene.2010.73","volume":"12","author":"B Namjou","year":"2011","unstructured":"Namjou, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12, 270\u2013279 (2011).","journal-title":"Genes Immun."},{"key":"BFnrrheum201831_CR144","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513443","volume":"80","author":"G Rice","year":"2007","unstructured":"Rice, G. et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80, 811\u2013815 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201831_CR145","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ng2091","volume":"39","author":"MA Lee-Kirsch","year":"2007","unstructured":"Lee-Kirsch, M. A. et al. Mutations in the gene encoding the 3\u2032-5\u2032 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39, 1065\u20131067 (2007).","journal-title":"Nat. Genet."},{"key":"BFnrrheum201831_CR146","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10875-015-0147-3","volume":"35","author":"GI Rice","year":"2015","unstructured":"Rice, G. I., Rodero, M. P. & Crow, Y. J. Human disease phenotypes associated with mutations in TREX1. J. Clin. Immunol. 35, 235\u2013243 (2015).","journal-title":"J. Clin. Immunol."},{"key":"BFnrrheum201831_CR147","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajhg.2014.11.019","volume":"96","author":"MA Jang","year":"2015","unstructured":"Jang, M. A. et al. Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome. Am. J. Hum. Genet. 96, 266\u2013274 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrrheum201831_CR148","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3389\/fimmu.2017.00927","volume":"8","author":"A Torrelo","year":"2017","unstructured":"Torrelo, A. CANDLE syndrome as a paradigm of proteasome-related autoinflammation. Front. Immunol. 8, 927 (2017).","journal-title":"Front. Immunol."},{"key":"BFnrrheum201831_CR149","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","volume":"125","author":"A Brehm","year":"2015","unstructured":"Brehm, A. et al. Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production. J. Clin. Invest. 125, 4196\u20134211 (2015).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum201831_CR150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507\u2013518 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"BFnrrheum201831_CR151","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1084\/jem.20171351","volume":"214","author":"James D. Warner","year":"2017","unstructured":"Warner, J. D. et al. STING-associated vasculopathy develops independently of IRF3 in mice. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20171351 (2017).","journal-title":"The Journal of Experimental Medicine"},{"key":"BFnrrheum201831_CR152","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","volume":"70","author":"JT Merrill","year":"2011","unstructured":"Merrill, J. T. et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70, 1905\u20131913 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR153","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","volume":"64","author":"JM McBride","year":"2012","unstructured":"McBride, J. M. et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64, 3666\u20133676 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR154","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","volume":"65","author":"M Petri","year":"2013","unstructured":"Petri, M. et al. Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 65, 1011\u20131021 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrrheum.2016.83","volume":"12","author":"TB Niewold","year":"2016","unstructured":"Niewold, T. B. Connective tissue diseases: Targeting type I interferon in systemic lupus erythematosus. Nat. Rev. Rheumatol. 12, 377\u2013378 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrrheum201831_CR156","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta, M. et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909\u20131916 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR157","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","volume":"75","author":"KC Kalunian","year":"2016","unstructured":"Kalunian, K. C. et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. 75, 196\u2013202 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR158","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","volume":"65","author":"BR Lauwerys","year":"2013","unstructured":"Lauwerys, B. R. et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1-kinoid. Arthritis Rheum. 65, 447\u2013456 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201831_CR159","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs, B. W. et al. A phase Ib clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann. Rheum. Dis. 73, 256\u2013262 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR160","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/19420862.2015.1007810","volume":"7","author":"L Peng","year":"2015","unstructured":"Peng, L., Oganesyan, V., Wu, H., Dall'Acqua, W. F. & Damschroder, M. M. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-\u03b1 receptor 1 antibody. mAbs 7, 428\u2013439 (2015).","journal-title":"mAbs"},{"key":"BFnrrheum201831_CR161","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie, R. et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376\u2013386 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201831_CR162","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/jid.2015.188","volume":"135","author":"X Guo","year":"2015","unstructured":"Guo, X. et al. Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. J. Invest. Dermatol. 135, 2402\u20132409 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrrheum201831_CR163","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature22821","volume":"546","author":"AR Bialas","year":"2017","unstructured":"Bialas, A. R. et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 546, 539\u2013543 (2017).","journal-title":"Nature"},{"key":"BFnrrheum201831_CR164","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre, K., Criswell, L. A. & McCune, J. M. Hydroxychloroquine is associated with impaired interferon-\u03b1 and tumor necrosis factor-\u03b1 production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 14, R155 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201831_CR165","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168\u20131172 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201831_CR166","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706\u20131713 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"BFnrrheum201831_CR167","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"Claire Rempenault","year":"2017","unstructured":"Rempenault, C. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211836 (2017).","journal-title":"Annals of the Rheumatic Diseases"},{"key":"BFnrrheum201831_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03085940 (2017)."},{"key":"BFnrrheum201831_CR169","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02595346 (2016)."},{"key":"BFnrrheum201831_CR170","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01379573 (2017)."},{"key":"BFnrrheum201831_CR171","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03030118 (2018)."},{"key":"BFnrrheum201831_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603146 (2017)."},{"key":"BFnrrheum201831_CR173","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/13543784.2016.1162291","volume":"25","author":"M Postal","year":"2016","unstructured":"Postal, M., Sinicato, N. A., Appenzeller, S. & Niewold, T. B. Drugs in early clinical development for systemic lupus erythematosus. Expert Opin. Invest. Drugs 25, 573\u2013583 (2016).","journal-title":"Expert Opin. Invest. Drugs"},{"key":"BFnrrheum201831_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03241108 (2017)."},{"key":"BFnrrheum201831_CR175","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02592434 (2018)."},{"key":"BFnrrheum201831_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01500551 (2018)."},{"key":"BFnrrheum201831_CR177","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03000439 (2018)."},{"key":"BFnrrheum201831_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01976364 (2018)."},{"key":"BFnrrheum201831_CR179","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01882439 (2017)."},{"key":"BFnrrheum201831_CR180","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01877668 (2017)."},{"key":"BFnrrheum201831_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03159936 (2017)."},{"key":"BFnrrheum201831_CR182","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02535689 (2018)."},{"key":"BFnrrheum201831_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03288324 (2018)."},{"key":"BFnrrheum201831_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03002649 (2017)."},{"key":"BFnrrheum201831_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02265705 (2017)."},{"key":"BFnrrheum201831_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01721044 (2018)."},{"key":"BFnrrheum201831_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01885078 (2018)."},{"key":"BFnrrheum201831_CR188","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01721057 (2017)."},{"key":"BFnrrheum201831_CR189","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01710358 (2017)."},{"key":"BFnrrheum201831_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01711359 (2017)."},{"key":"BFnrrheum201831_CR191","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01724580 (2017)."},{"key":"BFnrrheum201831_CR192","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065700 (2017)."},{"key":"BFnrrheum201831_CR193","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01894516 (2016)."},{"key":"BFnrrheum201831_CR194","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01888874 (2016)."},{"key":"BFnrrheum201831_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01668641 (2013)."},{"key":"BFnrrheum201831_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01384422 (2012)."},{"key":"BFnrrheum201831_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02885181 (2017)."},{"key":"BFnrrheum201831_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03320876 (2018)."},{"key":"BFnrrheum201831_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03101670 (2018)."},{"key":"BFnrrheum201831_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03285711 (2018)."},{"key":"BFnrrheum201831_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02996500 (2018)."},{"key":"BFnrrheum201831_CR202","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.3643","volume":"18","author":"Y Liang","year":"2017","unstructured":"Liang, Y. et al. A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat. Immunol. 18, 152\u2013160 (2017).","journal-title":"Nat. Immunol."},{"key":"BFnrrheum201831_CR203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-1759(96)00168-8","volume":"199","author":"U Canosi","year":"1996","unstructured":"Canosi, U. et al. A highly precise reporter gene bioassay for type I interferon. J. Immunol. Methods 199, 69\u201376 (1996).","journal-title":"J. Immunol. Methods"},{"key":"BFnrrheum201831_CR204","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jmb.2004.07.065","volume":"342","author":"KS Khabar","year":"2004","unstructured":"Khabar, K. S. et al. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J. Mol. Biol. 342, 833\u2013846 (2004).","journal-title":"J. Mol. Biol."},{"key":"BFnrrheum201831_CR205","doi-asserted-by":"crossref","first-page":"948364","DOI":"10.1155\/2010\/948364","volume":"2010","author":"TB Niewold","year":"2010","unstructured":"Niewold, T. B., Clark, D. N., Salloum, R. & Poole, B. D. Interferon \u03b1 in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010, 948364 (2010).","journal-title":"J. Biomed. Biotechnol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.31","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2018.31","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:43:00Z","timestamp":1684471380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2018.31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":205,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFnrrheum201831"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2018.31","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"21 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.B.N. declares that he has received research grants from EMD Serono and Janssen. T.L.W.N declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}